Teva Settles Provigil Pay-For-Delay Class Action; Will FTC Deal Follow?
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva plays it safe in $512 million agreement with direct purchasers, even though AstraZeneca won a jury verdict in similar suit, the first to go to trial since Supreme Court’s FTC v. Actavis decision.
You may also be interested in...
Namenda Product Hopping Settlement Surpasses Most Recent DOJ Agreements
Direct purchasers' $750m settlement with Allergan is at least the second involving product hopping claims; only one DOJ settlement surpassed this amount in the past year.
Teva Settles 16-Year Cipro Pay-For-Delay Litigation For $225M; Will Focus Shift To Pricing Deals?
California indirect purchasers reached previous settlements with Bayer and three other firms; plaintiffs’ attorney sees shift from reverse-payment to price fixing and market swapping cases. Trump appointments to FTC could influence direction of scrutiny.
Teva Settles 16-Year Cipro Pay-For-Delay Litigation For $225M; Will Focus Shift To Pricing Deals?
California indirect purchasers reached previous settlements with Bayer and three other firms; plaintiffs’ attorney sees shift from reverse-payment to price fixing and market swapping cases. Trump appointments to FTC could influence direction of scrutiny.